Life Sciences
Navigating Funding Uncertainty: Strategies for Life Sciences Organizations to Mitigate Risk
In the life sciences sector, where innovation often relies on grant funding, financial stability has become increasingly uncertain. Federal budget constraints and shifting political priorities pressure organizations to adopt a proactive approach to managing grants. As opposed to reacting to changes as they happen, AAFCPAs advises that clients anticipate potential funding risks and implement strategies […]
Managing Cash Flow and Expenses in Life Sciences
In this article: Managing cash flow presents ongoing challenges for those in the life sciences, particularly those navigating pre-clinical research and early clinical stages. With significant resources devoted to research and development (R&D), precise cash tracking across R&D and general and administrative (G&A) categories is essential for sustaining growth and demonstrating financial responsibility. Distinguishing between […]
Tax Strategies Shaping Life Science Innovation
Life science companies, particularly those in the start-up or growth phase, are challenged with balancing their core mission, e.g., advancing scientific discovery, with the complex financial and tax issues that arise in the process. While pursuing breakthroughs in areas like cancer treatments or novel drugs, companies need to also ensure they retain enough capital to […]
Tax Planning For Life Sciences Amid Shifting Policies
Life Science Leader (February 11,2025) – In the life sciences sector, maintaining a strategic approach to tax planning has become increasingly complex, especially with ongoing regulatory changes affecting mergers, acquisitions, and how we treat research and development (R&D) expenses. Such tax policy shifts can directly affect corporate structure decisions, overall business strategy, and the ability […]
R&D Expenditures for Early Stage and Life Science Start-ups
Could your startup benefit from research and development (R&D) tax credits? Have you explored whether or not you qualify? Are you prepared to navigate tax strategies that could ease financial pressures on innovation? For early-stage and life science startups, R&D drives progress and lays the foundation for growth. However, recent changes to tax law—specifically Section […]
How Life Sciences May Be Affected by New Administration Tax Policies
In this article: For clients in the life sciences, tax policies often hinge on a shifting political landscape. This means, each new administration may signal changes that could reshape strategies in the coming year and beyond. Understanding emerging policies will be key in 2025 for areas like M&A timing, R&D cost management, and structuring for […]
Bill Introduced to Repeal R&D Expense Capitalization
AAFCPAs provides the following update to clients with expenditures incurred in connection with your trade or business which represent research and development costs in the experimental or laboratory sense. On Thursday, March 16th, Senators Maggie Hassan (D) of New Hampshire and Todd Young (R) of Indiana reintroduced a bill to repeal the required capitalization of […]